Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
October 31, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...
Cassava Sciences Resolves SEC Investigation
September 26, 2024 18:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
September 24, 2024 08:30 ET
|
Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended Both Phase 3 Trials...
Cassava Sciences Names Rick Barry as Chief Executive Officer
September 09, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a...
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 08:31 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
August 08, 2024 08:00 ET
|
Cassava Sciences, Inc.
$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for...
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
August 05, 2024 09:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson. We are profoundly saddened by the...
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
August 01, 2024 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...
Cassava Sciences Announces Expansion of Open-Label Extension Trials
July 30, 2024 08:15 ET
|
Cassava Sciences, Inc.
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on...
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024 08:00 ET
|
Cassava Sciences, Inc.
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 ...